期刊
DRUG DISCOVERY TODAY
卷 15, 期 1-2, 页码 71-77出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2008.12.010
关键词
-
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084551] Funding Source: NIH RePORTER
- NIAID NIH HHS [R01 AI084551] Funding Source: Medline
Rapid growth in the development of new tools and advances in molecular immunology has led to a class of drugs called biologics. While effective, these therapies are costly, typically require continuous administration and often have serious side effects. This review focuses on current therapies and the need for a new class of therapies. A novel class of drugs able to induce and maintain tolerance will be paralleled with the notion that combination therapy appropriately tailored to patient subpopulations may hold the promise of less costly and more effective therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据